Takeda Signs an Exclusive Multi-Target Research Agreement with Sosei Heptares to Develop and Commercialize Therapies Modulating GPCR

Takeda Signs an Exclusive Multi-Target Research Agreement with Sosei Heptares to Develop and Commercialize Therapies Modulating GPCR

Shots:

  • Sosei Heptares to receive $26M up front, R&D funding, $1.2B+ development & commercial milestones and royalties on sales of the licensed products. Takeda to get WW rights to develop & commercialize therapies for each target through specified pharmacological approaches in the collaboration
  • The focus of the agreement is to develop multiple GPCR targets nominated by Takeda by combining Sosei Heptares’ GPCR-focused structure-based drug design capabilities with Takeda’s expertise in discovery, development and therapeutic area
  • The partners initially work on GI targets to discover therapies for gut inflammation and motility disorders with an expected expansion of an agreement in other therapeutic areas

Click here to­ read full press release/ article | Ref: Sosei Heptares | Image: The Boston Globe